GSK2256098

DRUG4 trials

Sponsors

GlaxoSmithKline, University Health Network, Toronto

Conditions

AdenocarcinomaCancerNeoplasmsPancreatic Cancer

Phase 1

Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers

CompletedNCT00996671

GlaxoSmithKlineCancer

Start: 2009-11-06End: 2010-03-17Updated: 2017-06-14

Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors

CompletedNCT01138033

GlaxoSmithKlineCancer

Start: 2010-07-27End: 2015-12-21Updated: 2017-05-11

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

CompletedNCT01938443

GlaxoSmithKlineCancer, Neoplasms

Start: 2013-11-18End: 2016-06-23Updated: 2019-07-12

Phase 2

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

CompletedNCT02428270

University Health Network, TorontoAdenocarcinoma, Pancreatic Cancer

Start: 2016-04-30End: 2022-10-27Updated: 2022-11-01

Related Papers

A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).

Journal of Clinical Oncology2018-02-0124 citations

A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.

Journal of Clinical Oncology2015-05-207 citations